Empowered Patient Podcast

Cindy Gaines is Chief Clinical Transformation Officer at Lumeon, a clinical workflow automation company. While standard practices are often in place in a healthcare setting, leadership is often surprised at the variations in execution and the opportunities for automation. The goal is to use technology to extend the providers' practice and serve the patients in a familiar, convenient fashion.

Cindy elaborates, "As much as we think we have standardized workflows today, I will talk to leaders who are like, "Oh, this is how we do it." And when you talk to the front lines, "How do you do this work? " you find a lot more variation out there than expected by the leadership team. So, that's sometimes where the consulting part of this company comes in. Some people think we're much more standardized than we are, and that's the opportunity to take those standardized workflows and make them easier for the teams to follow. It's this gap between clinical intent and clinical execution."

"So when you think foundationally about a medical record, it meets the organization's needs but can't take care of everything by itself. That's why I believe other solutions and organizations are looking for solutions that can work in collaboration with their EMRs. That's, again, when I think about clinical workflow automation. It's about how it works as an agility layer with your EMR. Not to compete with it but to extend an EMR's capabilities. That's the opportunity people are looking for with those solutions that can extend the capability instead of competing with the capability."

"If one benefit came out of COVID, it helped people embrace this in the environment. Before COVID, I used to hear providers, when you talked about virtual care and patients actually doing things themselves, it'd be, "Oh, my patients, they're too elderly to do that. They couldn't manage this technology." COVID forced us, in many ways, to advance technology for our customers and consumers. And suddenly, you had 70 and 80-year-olds doing virtual visits, and they didn't want them to go away after COVID."

#Lumeon #AutomatedCare #CareAutomation #CareOrchestration #ClinicalWorkflowAutomation #ClinicalWorkflow #PatientExperience #DigitalTransformation

lumeon.com

Listen to the podcast here

Cindy Gaines is Chief Clinical Transformation Officer at Lumeon, a clinical workflow automation company. While standard practices are often in place in a healthcare setting, leadership is often surprised at the variations in execution and the opportunities for automation. The goal is to use technology to extend the providers' practice and serve the patients in a familiar, convenient fashion.

Cindy elaborates, "As much as we think we have standardized workflows today, I will talk to leaders who are like, "Oh, this is how we do it." And when you talk to the front lines, "How do you do this work? " you find a lot more variation out there than expected by the leadership team. So, that's sometimes where the consulting part of this company comes in. Some people think we're much more standardized than we are, and that's the opportunity to take those standardized workflows and make them easier for the teams to follow. It's this gap between clinical intent and clinical execution."

"So when you think foundationally about a medical record, it meets the organization's needs but can't take care of everything by itself. That's why I believe other solutions and organizations are looking for solutions that can work in collaboration with their EMRs. That's, again, when I think about clinical workflow automation. It's about how it works as an agility layer with your EMR. Not to compete with it but to extend an EMR's capabilities. That's the opportunity people are looking for with those solutions that can extend the capability instead of competing with the capability."

"If one benefit came out of COVID, it helped people embrace this in the environment. Before COVID, I used to hear providers, when you talked about virtual care and patients actually doing things themselves, it'd be, "Oh, my patients, they're too elderly to do that. They couldn't manage this technology." COVID forced us, in many ways, to advance technology for our customers and consumers. And suddenly, you had 70 and 80-year-olds doing virtual visits, and they didn't want them to go away after COVID."

#Lumeon #AutomatedCare #CareAutomation #CareOrchestration #ClinicalWorkflowAutomation #ClinicalWorkflow #PatientExperience #DigitalTransformation

lumeon.com

Download the transcript here

Dr. Darrin Starkey, Director of Education at Trace Minerals Research, emphasizes the need for a wholesome, balanced diet and the challenges people face to get necessary nutrients from the food we eat. Of particular concern are the trace elements not present in processed foods.

Darrin explains, "We are typically familiar with macrominerals, calcium, magnesium, potassium, phosphorus, and sodium. But trace minerals are often overlooked and neglected because they're needed in small amounts. So, in answer to that question, they're the trace amounts of these elements that our bodies need that make up 0.01% of our makeup and yet an essential part of our health that we often don't focus on until we're in a crisis."

"But often, because of our society, we're such a reactive society today instead of being proactive. We should wait until we're in crisis before asking the questions. But often, being proactive, of being able to put and supplement these trace minerals back into our diets, is a huge point. If we look at the variety of available foods and how we can support local growers and the waters we choose to drink, we have a lot of opportunities to minimize these deficiencies. In the society in which we live, it's critical that we put these trace minerals back in on a daily basis."

"At Trace Minerals, our niche is putting these trace minerals back into all of our products. But our foundational product is our ConcenTrace Trace Mineral drops, and that's the foundational product that most people are familiar with. We want our listeners and consumers to understand that we're trying to do our part in the delivery system of these products. Because, as you well know, trace minerals don't taste good in a pure, concentrated state. They're very strong. So, we have to learn how to dilute those. And for those with sensitive taste buds, we offer them in tablet form, capsule form, and effervescent form. We're doing our part in helping the consumer find a way to deliver these daily that makes it enjoyable."

#TraceMinerals #TraceMineralsResearch #Remineralize #Supplements #PerformanceNutrition #Hydration #Immunity #HealthandWellness #Electrolytes

traceminerals.com

Listen to the podcast here

Dr. Darrin Starkey, Director of Education at Trace Minerals Research, emphasizes the need for a wholesome, balanced diet and the challenges people face to get necessary nutrients from the food we eat. Of particular concern are the trace elements not present in processed foods.

Darrin explains, "We are typically familiar with macrominerals, calcium, magnesium, potassium, phosphorus, and sodium. But trace minerals are often overlooked and neglected because they're needed in small amounts. So, in answer to that question, they're the trace amounts of these elements that our bodies need that make up 0.01% of our makeup and yet an essential part of our health that we often don't focus on until we're in a crisis."

"But often, because of our society, we're such a reactive society today instead of being proactive. We should wait until we're in crisis before asking the questions. But often, being proactive, of being able to put and supplement these trace minerals back into our diets, is a huge point. If we look at the variety of available foods and how we can support local growers and the waters we choose to drink, we have a lot of opportunities to minimize these deficiencies. In the society in which we live, it's critical that we put these trace minerals back in on a daily basis."

"At Trace Minerals, our niche is putting these trace minerals back into all of our products. But our foundational product is our ConcenTrace Trace Mineral drops, and that's the foundational product that most people are familiar with. We want our listeners and consumers to understand that we're trying to do our part in the delivery system of these products. Because, as you well know, trace minerals don't taste good in a pure, concentrated state. They're very strong. So, we have to learn how to dilute those. And for those with sensitive taste buds, we offer them in tablet form, capsule form, and effervescent form. We're doing our part in helping the consumer find a way to deliver these daily that makes it enjoyable."

#TraceMinerals #TraceMineralsResearch #Remineralize #Supplements #PerformanceNutrition #Hydration #Immunity #HealthandWellness #Electrolytes

traceminerals.com

Download the transcript here

Eric Mayer, CEO of New Day Diagnostics, is tapping into the trend for more user-friendly diagnostics that patients can use to test themselves for making medical decisions. While blood draw facilities and complex testing will always be a component of healthcare, as technology progresses, more at-home testing will become available. To better support patients and providers, New Day is finding less invasive ways to collect biomarker information and using AI and machine learning to refine the interpretation of test results.

Eric explains, "The business model is very straightforward. We design and develop our suite of diagnostic products that cover cancer testing, infectious disease testing, digestive disease, and women's health. We also operate a contract research laboratory and CRO services for other diagnostics developers, whether point-of-care or over-the-counter, who want to bring those products through the FDA. We help with those studies, and we help with the clinical trials. And then, we also deploy diagnostics. We operate a clinical laboratory where we can drive patient results through the tests that we deploy and have a network of distributors and sales channels to get kitted products and kitted diagnostic tests out into the field once they're approved."

"Depending on the type of test or the type of disease we're trying to detect, there are some that are just a yes-no. It's sort of a qualitative result. Either the virus or that bacteria is or is not there. Then, there's another for measuring numerous biomarkers in a blood sample. A liquid biopsy is a great example. At New Day Diagnostics, we incorporate AI and machine learning to combine advanced mathematics and science and distill it down to what we believe is a very easy-to-understand result for that physician and for that patient to understand. That is absolutely right. It doesn't help anybody if its result is just a mishmash of numbers without any clinical usefulness for what that result represents."

#NewDayDiagnostics #Diagnostics #Cancer #InfectiousDiseases #WomensHealth #GastrointestinalDiseases #Biomarkers

newdaydiagnostics.com

Listen to the podcast here

Eric Mayer, CEO of New Day Diagnostics, is tapping into the trend for more user-friendly diagnostics that patients can use to test themselves for making medical decisions. While blood draw facilities and complex testing will always be a component of healthcare, as technology progresses, more at-home testing will become available. To better support patients and providers, New Day is finding less invasive ways to collect biomarker information and using AI and machine learning to refine the interpretation of test results.

Eric explains, "The business model is very straightforward. We design and develop our suite of diagnostic products that cover cancer testing, infectious disease testing, digestive disease, and women's health. We also operate a contract research laboratory and CRO services for other diagnostics developers, whether point-of-care or over-the-counter, who want to bring those products through the FDA. We help with those studies, and we help with the clinical trials. And then, we also deploy diagnostics. We operate a clinical laboratory where we can drive patient results through the tests that we deploy and have a network of distributors and sales channels to get kitted products and kitted diagnostic tests out into the field once they're approved."

"Depending on the type of test or the type of disease we're trying to detect, there are some that are just a yes-no. It's sort of a qualitative result. Either the virus or that bacteria is or is not there. Then, there's another for measuring numerous biomarkers in a blood sample. A liquid biopsy is a great example. At New Day Diagnostics, we incorporate AI and machine learning to combine advanced mathematics and science and distill it down to what we believe is a very easy-to-understand result for that physician and for that patient to understand. That is absolutely right. It doesn't help anybody if its result is just a mishmash of numbers without any clinical usefulness for what that result represents."

#NewDayDiagnostics #Diagnostics #Cancer #InfectiousDiseases #WomensHealth #GastrointestinalDiseases #Biomarkers

newdaydiagnostics.com

Download the transcript here

Dr. Ed Chekan is certified in general surgery and is Vice President of Medical Affairs and Professional Education at Asensus Surgical, which is taking the platform of laparoscopic surgery and adding augmented intelligence technology. Laparoscopic surgery currently starts with a digital interface in a video image. Asensus is adding augmented intelligence to the video image in real-time to support the surgeon and surgical team with additional information to improve outcomes and the experience of the clinicians.

Ed explains, "We're starting with things already being done. We have a feature that is a digital measurement. This allows the surgeon, if measurement is critical to this portion of the procedure, for instance, in general surgery, we'd say five to six centimeters from the pylorus, to start a staple line in a sleeve gastrectomy. We either estimate that through different ways, or we'd have to put a tape measure inside the patient to measure that distance accurately to get that measurement. So we're doing that now digitally."

"We have a telemanipulator. Our Asensus system is currently the second telemanipulator to be approved in the US. And so, we have it in a few centers already. And that integrates into the operating room as separate arms on separate pods or platforms that can be moved around, connected to a cockpit or a console, where the surgeon sits to do the manipulating."

"Then, the video feeds feed into our Intelligent Surgical Unit or ISU, and those video images are processed and sent to the cloud. We'll store them, we could annotate them, and we can also use them to influence, in real-time, certain types of feedback based on what would be interpreted from the video image. So, someone else is watching the video. The computer is watching the video, too, to tell you things that are happening."

@AsensusSurgical #Asensus #Robotics #DigitalStrategy #Surgery #IntraoperativeClinicalIntelligence #AugmentIntelligence

asensus.com

Listen to the podcast here

Dr. Ed Chekan is certified in general surgery and is Vice President of Medical Affairs and Professional Education at Asensus Surgical, which is taking the platform of laparoscopic surgery and adding augmented intelligence technology. Laparoscopic surgery currently starts with a digital interface in a video image. Asensus is adding augmented intelligence to the video image in real-time to support the surgeon and surgical team with additional information to improve outcomes and the experience of the clinicians.

Ed explains, "We're starting with things already being done. We have a feature that is a digital measurement. This allows the surgeon, if measurement is critical to this portion of the procedure, for instance, in general surgery, we'd say five to six centimeters from the pylorus, to start a staple line in a sleeve gastrectomy. We either estimate that through different ways, or we'd have to put a tape measure inside the patient to measure that distance accurately to get that measurement. So we're doing that now digitally."

"We have a telemanipulator. Our Asensus system is currently the second telemanipulator to be approved in the US. And so, we have it in a few centers already. And that integrates into the operating room as separate arms on separate pods or platforms that can be moved around, connected to a cockpit or a console, where the surgeon sits to do the manipulating."

"Then, the video feeds feed into our Intelligent Surgical Unit or ISU, and those video images are processed and sent to the cloud. We'll store them, we could annotate them, and we can also use them to influence, in real-time, certain types of feedback based on what would be interpreted from the video image. So, someone else is watching the video. The computer is watching the video, too, to tell you things that are happening."

@AsensusSurgical #Asensus #Robotics #DigitalStrategy #Surgery #IntraoperativeClinicalIntelligence #AugmentIntelligence

asensus.com

Download the transcript here

Lynn Carroll, Chief Operating Officer at HSBlox, provides a platform to encourage collaboration between payers and providers in a value-based care system. The success of VBC is based on the perspective of the patient and the ability to personalize the interaction with their entire care team. Assessing the needs of patients and using digital tools to engage patients is bringing the benefits of value-based care to a broader audience.

Lynn explains, "On the data exchange side, this certainly gets us into the interoperability space. What we have seen is an emphasis on aligning the participants in the care team. Part of an assessment is to understand who a patient is seeing today, who they may have seen recently, or who are they not seeing anyone. But once you know the care team and that care team is in place, facilitating that data sharing component is a key part of the approach."

"We have seen an attempt after stratifying a population to know where there are high-touch patients or folks with chronic disease that can have monitoring applied. The challenge with those tools is to make sure that you engage the patient and give them the ability to understand their role in utilizing those tools. So, if you think about part of the assessment upfront, it is also to understand a given patient's motivation and/or capability to take responsibility for participating in these programs."

#CommunityHealth #Healthcare #HealthEquity #ManagedCare #PatientEngagement #ValueBasedCare #VBC #ValueBasedAdministration

hsblox.com

Listen to the podcast here

Lynn Carroll, Chief Operating Officer at HSBlox, provides a platform to encourage collaboration between payers and providers in a value-based care system. The success of VBC is based on the perspective of the patient and the ability to personalize the interaction with their entire care team. Assessing the needs of patients and using digital tools to engage patients is bringing the benefits of value-based care to a broader audience.

Lynn explains, "On the data exchange side, this certainly gets us into the interoperability space. What we have seen is an emphasis on aligning the participants in the care team. Part of an assessment is to understand who a patient is seeing today, who they may have seen recently, or who are they not seeing anyone. But once you know the care team and that care team is in place, facilitating that data sharing component is a key part of the approach."

"We have seen an attempt after stratifying a population to know where there are high-touch patients or folks with chronic disease that can have monitoring applied. The challenge with those tools is to make sure that you engage the patient and give them the ability to understand their role in utilizing those tools. So, if you think about part of the assessment upfront, it is also to understand a given patient's motivation and/or capability to take responsibility for participating in these programs."

#CommunityHealth #Healthcare #HealthEquity #ManagedCare #PatientEngagement #ValueBasedCare #VBC #ValueBasedAdministration #DigitalHealth

hsblox.com

Download the transcript here